These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20101750)

  • 1. Tolvaptan and hyponatremia in a patient with cirrhosis.
    Boyer TD
    Hepatology; 2010 Feb; 51(2):699-702. PubMed ID: 20101750
    [No Abstract]   [Full Text] [Related]  

  • 2. Massive aquaresis after tolvaptan administration and albumin infusion in a patient with alcoholic cirrhosis.
    Cho C; Logan JL; Lien YH
    Am J Med; 2012 Jan; 125(1):e5-6. PubMed ID: 22075044
    [No Abstract]   [Full Text] [Related]  

  • 3. Tolvaptan (Samsca) for hyponatremia.
    Med Lett Drugs Ther; 2009 Nov; 51(1326):95-6. PubMed ID: 20224525
    [No Abstract]   [Full Text] [Related]  

  • 4. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.
    Cárdenas A; Ginès P; Marotta P; Czerwiec F; Oyuang J; Guevara M; Afdhal NH
    J Hepatol; 2012 Mar; 56(3):571-8. PubMed ID: 22027579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaptans and the treatment of water-retaining disorders.
    Quittnat F; Gross P
    Semin Nephrol; 2006 May; 26(3):234-43. PubMed ID: 16713496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on tolvaptan for the treatment of hyponatremia.
    Dasta JF; Chiong JR; Christian R; Friend K; Lingohr-Smith M; Lin J; Cassidy IB
    Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):399-410. PubMed ID: 22971027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of oral vasopressin V2 receptor antagonist for hyponatremia in acute brain injury.
    Jeon SB; Choi HA; Lesch C; Kim MC; Badjatia N; Claassen J; Mayer SA; Lee K
    Eur Neurol; 2013; 70(3-4):142-8. PubMed ID: 23887035
    [No Abstract]   [Full Text] [Related]  

  • 8. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
    Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolvaptan: a new tool for the effective treatment of hyponatremia in psychotic disorders.
    Josiassen RC; Curtis J; Filmyer DM; Audino B; Skuban N; Shaughnessy RA
    Expert Opin Pharmacother; 2010 Mar; 11(4):637-48. PubMed ID: 20163274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Vasopressin antagonist in hyponatremia. Rapid and simple control of serum sodium concentration].
    MMW Fortschr Med; 2012 Dec; 154(22):78-9. PubMed ID: 23297546
    [No Abstract]   [Full Text] [Related]  

  • 11. Double-blind, placebo-controlled, multicenter trial of a vasopressin V2-receptor antagonist in patients with schizophrenia and hyponatremia.
    Josiassen RC; Goldman M; Jessani M; Shaughnessy RA; Albazzaz A; Lee J; Ouyang J; Orlandi C; Czerwiec F
    Biol Psychiatry; 2008 Dec; 64(12):1097-100. PubMed ID: 18692175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of tolvaptan, an oral vasopressin V2 receptor antagonist, in hyponatremia.
    Madias NE
    Am J Kidney Dis; 2007 Aug; 50(2):184-7. PubMed ID: 17660019
    [No Abstract]   [Full Text] [Related]  

  • 13. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
    Palm C; Pistrosch F; Herbrig K; Gross P
    Am J Med; 2006 Jul; 119(7 Suppl 1):S87-92. PubMed ID: 16843091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Vasopressin V2-receptor antagonist, tolvaptan, for treatment of heart failure].
    Yamamura Y; Sato O; Fujiki H
    Nihon Rinsho; 2007 May; 65 Suppl 5():164-8. PubMed ID: 17571379
    [No Abstract]   [Full Text] [Related]  

  • 15. Chronic hyponatremia impairs memory in rats: effects of vasopressin antagonist tolvaptan.
    Miyazaki T; Ohmoto K; Hirose T; Fujiki H
    J Endocrinol; 2010 Jul; 206(1):105-11. PubMed ID: 20392812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
    Gheorghiade M; Niazi I; Ouyang J; Czerwiec F; Kambayashi J; Zampino M; Orlandi C;
    Circulation; 2003 Jun; 107(21):2690-6. PubMed ID: 12742979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists.
    Chen S; Jalandhara N; Batlle D
    Nat Clin Pract Nephrol; 2007 Feb; 3(2):82-95. PubMed ID: 17251996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Disorders of body water regulation and the therapy--vasopressin antagonists].
    Ishikawa S; Saito T
    Nihon Naika Gakkai Zasshi; 1997 Sep; 86(9):1654-9. PubMed ID: 9410978
    [No Abstract]   [Full Text] [Related]  

  • 19. Vasopressin excess and hyponatremia.
    Pham PC; Pham PM; Pham PT
    Am J Kidney Dis; 2006 May; 47(5):727-37. PubMed ID: 16632011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia.
    Gheorghiade M; Gottlieb SS; Udelson JE; Konstam MA; Czerwiec F; Ouyang J; Orlandi C;
    Am J Cardiol; 2006 Apr; 97(7):1064-7. PubMed ID: 16563917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.